RTP Mobile Logo
Submitted by web@researchtop... on Wed, 08/22/2012 - 10:28

In these audio proceedings from a symposium held in conjunction with the Oncology Nursing Society's 2012 Annual Congress, the invited oncology nursing professionals participating as part of our faculty panel present actual patient cases from their practices, setting the stage for faculty discussion of optimal therapeutic and supportive care strategies in breast cancer.

This content is available in a number of formats for listening on the go with a mobile device or in the office or at home on a computer.

Listen to audio excerpts

Track 1: Case discussion: A 52-year-old woman previously treated for locally advanced ER-positive, HER2-negative breast cancer (BC) presents with ER-positive, HER2-positive recurrent disease 18 months later
Track 2: Importance of a rebiopsy in patients with metastatic BC (mBC)
Track 3: Continuation of anti-HER2 therapy beyond disease progression in patients with trastuzumab-refractory mBC
Track 4: Role of anthracyclines in the treatment of elderly patients and those with comorbidities receiving adjuvant chemotherapy/trastuzumab
Track 5: Prognosis for patients with HER2-positive early BC
Track 6: Adjuvant trastuzumab-based therapy for patients with small, node-negative, HER2-positive BC
Track 7: Mode of action of lapatinib and patient adherence issues with the combination of lapatinib and capecitabine
Track 8: Complementary mechanisms of action of pertuzumab and trastuzumab
Track 9: Results from CLEOPATRA: A Phase III study of first-line docetaxel/trastuzumab with or without pertuzumab for HER2-positive mBC
Track 10: Mechanism of action of the antibody-drug conjugate trastuzumab emtansine (T-DM1)
Track 11: EMILIA: A Phase III study of T-DM1 versus capecitabine and lapatinib in HER2-positive locally advanced or metastatic BC previously treated with trastuzumab and a taxane
Track 12: Improvement in progression-free survival and relative lack of toxicity with T-DM1 compared to chemotherapy/trastuzumab
Track 13: Case discussion: A 66-year-old woman who underwent treatment for ER-positive, HER2-negative mBC in 2001 presents with diffuse skin metastases, lymphangitic spread and bilateral pleural effusions
Track 14: Chemotherapy versus endocrine treatment for patients with ER-positive, HER2-negative mBC
Track 15: Communicating goals of therapy in mBC
Track 16: Coping with the stresses of oncologic care
Track 17: A nurse’s perspective on the importance of humor, recreation and exercise in stress management
Track 18: Importance of providing support during active cancer therapy and end-of-life management
Track 19: Clinical activity of the antimicrotubule agent eribulin mesylate
Track 20: Balancing late-line therapeutic intervals and treatment-related side effects with patients’ lifestyle and activities
Track 21: Heterogeneity in response rates to late-line therapy among patients with mBC
Track 22: Perspective on the current status of bevacizumab in mBC
Track 23: Considerations in selection of late-line therapy for HER2-negative mBC
Track 24: Educating patients before initiating capecitabine
Track 25: Eribulin: Mechanism of action, side-effect management and considerations for dose adjustments
Track 26: Dose, schedule and outcomes with nanoparticle albumin-bound (nab) paclitaxel compared to docetaxel as first-line therapy for HER2-negative mBC
Track 27: Faculty viewpoints on the use of nab paclitaxel versus paclitaxel
Track 28: Ixabepilone: Mode of action, response rates, dosing and side effects
Track 29: BOLERO-2 results: Exemestane with or without the mTOR inhibitor everolimus in ER-positive locally advanced or metastatic BC refractory to nonsteroidal aromatase inhibitors
Track 30: Management of everolimus-associated mucositis and stomatitis
Track 31: Everolimus-related interstitial pneumonitis
Track 32: Perspectives on hormone therapy for male BC

 
FACULTY:
 
Georgia Litsas, MSN, ANP-BC, AOCNP
Nurse Practitioner
Breast Oncology Center
Dana-Farber Cancer Institute
Boston, Massachusetts
 
Joyce O’Shaughnessy, MD
Co-Director, Breast Cancer
Research Program
Baylor-Charles A Sammons
Cancer Center
Texas Oncology, PA
US Oncology
Dallas, Texas
 
Hope S Rugo, MD
Professor of Medicine
Director, Breast Oncology and
Clinical Trials Education
University of California, San
Francisco
Helen Diller Family
Comprehensive Cancer Center
San Francisco, California
 
G Lita Smith, RN, ACNP
NP Supervisor
University of Michigan
Comprehensive Cancer Center
Ann Arbor, Michigan
 
MODERATOR:
 
Neil Love, MD
Research To Practice
Miami, Florida